The CEO of Novo Nordisk will testify in the Senate HELP Committee tomorrow about the cost of popular diabetes and weight loss ...

As the Senate Committee on Health, Education, Labor and Pensions (HELP) gears up for a hearing tomorrow titled “Why Is Novo ...

It's the second lawsuit to be filed this year in Maine against insurance carriers that limit coverage of popular drugs like ...

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...

Novo Nordisk's blockbuster diabetes drug Ozempic will be eligible for U.S. government's price negotiations in less than a ...

Kelly criticised Winfrey for not pressing Harris with tough questions, especially on issues like gun control and the border ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...

Novo Nordisk A/S Chief Executive Officer Lars Fruergaard Jorgensen will use a familiar argument to defend the US prices of ...

Melissa Barber, a health economist at Yale University, said during Sanders’ roundtable Tuesday that her research has shown ...

Amid expectations that the popularity of GLP-1 drugs will decrease bariatric surgery rates, a Cleveland Clinic-led study found these surgeries might be more effective than GLP-1s for some patients.

As the demand for GLP-1 drugs like Ozempic and Wegovy increases with consumers eager to shed pounds, the supplement industry ...

Novo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing ...